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a b s t r a c t
In clinical trials recombinant-modiﬁed vaccinia virus Ankara expressing the Mycobacterium tubercu-
losis antigen 85A (MVA85A) induces approximately 10 times more effector T cells than any other
recombinant MVA vaccine. We have found that in BCG primed subjects MVA85A vaccination reduces
transforming growth factor beta 1 (TGF-1) mRNA in peripheral blood lymphocytes and reducesKeywords:
TGF-1
Regulatory T cells
T
TGF-1 protein in the serum, but increases IFN- ELISPOT responses to the recall antigen SK/SD.
TGF-1 is essential for the generation of regulatory T cells and we see a correlation across vacci-
nees between CD4+CD25hiFoxP3+ cells and TGF-1 serum levels. This apparent ability to counteract
regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic
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duberculosis vaccines.
. Introduction
Currently, the only tuberculosis (TB) vaccine available is BCG,
hich although largely ineffective at protecting against adult pul-
onary disease does confer some protection against severe TB in
hildhood and against leprosy [1]. Therefore, strategies for improv-
ng BCG efﬁcacy are required. Boosting BCGprimed T cell responses
itha secondvaccineencodinganantigenpresentwithinBCG(het-
rologous prime–boost) is a potential strategy for improving BCG
fﬁcacy.Modiﬁedvaccinia virusAnkara (MVA) is commonlyusedas
vector to deliver the antigen in heterologous prime–boost strate-
ies and has been useful in boosting T cell responses to intracellular
athogens such as HIV, malaria and hepatitis C [2–8]. Antigen 85A
s considered a leading candidate antigen for inclusion in a booster
accine for BCG. It is immunodominant in animal and human stud-
es, is highly conserved amongst all mycobacterial species and is
resent in all strains of BCG. Using a recombinant MVA express-
ng antigen 85A (MVA85A) to boost previous BCG vaccination in
ALB/c mice induces higher levels of antigen-speciﬁc IFN- secret-
ng T cells and higher levels of protection from Mycobacterium
uberculosis (M. tb) challenge than BCG alone [9,10]. We have been
nvestigating the safety and immunogenicity of MVA85A in BCG
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aïve and BCG primed subjects in the UK [11,12]. In these stud-
es, MVA85A has been found to induce levels of IFN- secreting
ffector T cells approximately 10 times greater than those obtained
ith any other MVA vaccine construct. The effects of MVA85A
accination on T cell regulatory mechanisms that typically limit
ffector T cell responses have not been previously investigated.
oxP3 is a master gene governing the development and function
f regulatory T cells. Expression of FoxP3 in transgenic mice and
ctopic expression of FoxP3 in human cells has been shown to
enetically reprogramTcells to a regulatoryphenotype [13,14].Nat-
rally occurring regulatory T cells are generated in the thymus are
D4+CD25highandconstitute1–5%of circulatingCD4+cells. Trans-
orming growth factor beta 1 (TGF-1) is ubiquitously present in a
ide variety of cells and has opposing effects on the differentia-
ion and proliferation of multiple immune-cell types [15,16]. T cells
arry the TGF-1RI and TGF-1RII receptors and can be directly
nﬂuenced through binding of active TGF-1. TGF-1 is also a key
egulatorof the signalingpathways that initiate andmaintainFoxP3
xpression and is essential for the generation and suppressive func-
ion of peripheral regulatory T cells [13,17,18]. Previously we have
ound that TGF-1 is associated with the generation of regulatory
cells and higher rates of parasitic growth in subjects infected
Open access under CC BY license.ith Plasmodium falciparum [19]. The aim of this current study was
o determine the effect of vaccination with MVA85A, both in BCG
aïve and BCG primed subjects, on the immunoregulatory cytokine
GF-1 and on the generation of regulatory CD4+CD25hiFoxP3+ T
ells.
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. Materials and methods
.1. Clinical trials
Subjects were recruited for immunisation studies under pro-
ocols approved by the Medicines and Healthcare products
egulatory Agency and Oxfordshire Research Ethics Commit-
ee and enrolled only after obtaining written informed consent.
ww.clinicaltrials.gov identiﬁers: NCT00480688, NCT00423566,
CT00480714 and NCT00427830. They were aged 18–55 and were
ll seronegative for HIV, HBV and HCV at screening. Routine lab-
ratory haematology and biochemistry were performed prior to
accination and all values were within normal limits. Subjects vac-
inated with either BCG alone or MVA85A alone had no history of
revious BCG vaccination, no evidence of BCG scar, were ELISPOT
egative for the M. tb-speciﬁc antigens ESAT-6 and CFP-10 and had
PD responses on ELISPOT ranging from 0 to 68 (median 22) SFC
er 106 PBMC. Subjects vaccinated with BCG followed by MVA85A
ad received BCG vaccination 10–20 years prior to screening, had a
isible BCG scar, were ELISPOT negative for the M. tb-speciﬁc anti-
ens ESAT-6 and CFP-10 and had PPD ELISPOT responses ranging
rom 0 to 465 (median 177) SFC per 106 PBMC. All subjects were
ollowed-up for 6months,with blood samples taken at regular time
oints. Two subjects had previously been vaccinated with vaccinia,
lthough none had received a vaccination with MVA. Pre-existing
mmunity to vaccinia did not appear to effect the immune response
o MVA85A.
.2. IFN- ELISPOT assay
The main immunological measure used to determine vaccine
mmunogenicitywas the ex vivo IFN-ELISPOT. Thiswasperformed
n freshly isolated PBMC taken at the following time points: at the
ay of vaccination (0), and then at 1, 2, 4, 8, 12, 16, 24 and 52 weeks
fter vaccination aspreviously described [11]. Thesemeasurements
ere carried out on fresh PBMCs using 7 pools of 9–10 15-mer pep-
ides, overlapping by 10 amino acids (10g/ml). Brieﬂy, 300,000
BMCs per well were plated directly onto the ELISPOT plate (MAIP,
illipore) in the presence of peptide (7 pools of 9–10 15-mer pep-
ides overlapping by 10 amino acids, each pool ﬁnal concentration
0g/ml), Ag85A (10g/ml) and PPD (20g/ml), and incubated
or 18h. SK/SD (streptokinase–streptodornase) (250units and
0units/ml) and PHA 1g/ml were used in all assays as positive
ontrols. Assays were performed in duplicate and the results were
veraged.
.3. Cryopreservation of PBMC
PBMC were frozen in 1ml aliquots at a concentration of
×106 PBMC/ml. PBMC to be frozen were centrifuged and re-
uspended in 0.5ml fetal bovine serum (FBS). A 0.5ml aliquot of
reezing mix was then added to each tube (20% dimethyl sulfoxide,
0% FBS in RPMI). Cells were immediately transferred to a Nal-
ene “Mr. Frosty” freezing container and stored overnight at−80 ◦C.
nce frozen cells were transferred for long-term storage in liquid
itrogen.
.4. Cell stimulation for mRNA analysis
Frozen PBMC from weeks 0, 1, 4 and 12 from six BCG, eight
VA85A and eight BCG prime–MVA85A boost vaccinees were
hawed, washed and counted. 1×106 cells in R10 (RPMI 1640
ediumsupplementedwith 10% FBS, 2mM l-glutamine, 100 IU/ml
f penicillin and 100 IU/ml streptomycin) were plated in duplicate
n 96-well plates. One pool of 66 overlapping peptides for Ag85A
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15-mers overlapping by 10) was added to one duplicate well to a
nal concentration of 2g/ml each peptide. Antigen 85A peptide
timulated and media only control wells were incubated for 12h at
7 ◦C 5% CO2. After incubation media was removed and cells lysed
n 350l RLT buffer (RNeasy Minikit, Qiagen). Lysed cells in RLT
uffer were stored at −20 ◦C until extraction. For IFN- blocking
ssays, media was supplemented with 10g/ml anti-human IFN-
ntibodies (Becton Dickinson).
.5. Real-time reverse transcriptase (RT) PCR
TheRneasyMinikit (Qiagen)wasusedaccording to themanufac-
urers’ instructions for the extraction of total RNA from85Apeptide
timulated and media only control PBMC from each sample. Ten
icroliters of RNA extract was reverse transcribed in a total reac-
ionvolumeof20l usingoligo-dTand theOmniscriptKit (Qiagen).
DNA was stored at −20 ◦C until use. Real-time PCR was performed
sing the Roche LightCycler® and Quantitect mastermix (Qiagen).
Quantiﬁed, puriﬁed and diluted PCR product was used to gen-
rate external standard curves for each primer pair. Ct values were
onverted to copy number using these curves post-ampliﬁcation.
rimerswere designed for HPRT (F: 5′-TATGGACAGGACTGAACGTC-
′ and R: 5′-CTACAATGTGATGGCCTCCC-3′), FoxP3 (F: 5′-CACT-
ACAGGCACTCCTCCAGG-3′ and R: 5′-CCACCGTTGAGAGCTG-
TGCAT-3′) and TGF-1 (F: 5′-GGACATCAACGGGTTCACTA-3′ and
: 5′-CCGGTTCATGCCATGAATGG-3′). One microliter of cDNA was
sed in each reaction. Cycling conditions of an initial activation
tep of 15min at 95 ◦C followed by 45 cycles of 15 s at 94 ◦C, 20 s at
0 ◦C and 15 s at 72 ◦C were used for each primer pair.
.6. TGF-ˇ1 ELISA
Serum from weeks 0, 1, 4 and 12 from 6 BCG, 8 MVA85A and
1 BCG prime–MVA85A boost vaccinees were analysed for TGF-
1 protein using the human TGF-1 ELISA kit from eBioscience
San Diego, CA). Brieﬂy, serum was diluted 1/5 with PBS and 10l
N HCl added to 100l of diluted sample. After 10min incubation
amples were neutralised with 10l 1N NaOH and transferred to
pre-coated plate. Following an over night incubation at 4 ◦C the
olour was developed according to the manufacturers instructions
lates were read at 450nm/570nm in a MultiSkan (Thermo Life
ciences) plate reader.
.7. Flow cytometry
FoxP3 mRNA expression was conﬁrmed using intracellular
taining for FoxP3 protein. The anti-human Foxp3 antibody
PCH101 clone), CD4 FITC (RPA-T4), CD25 APC (BC96) were pur-
hased from eBioscience as part of the Human Regulatory T Cell
taining Kit (San Diego, CA). Intracellular staining for FoxP3 was
erformed on PBMC from subjects vaccinated with MVA85A alone
ccording to the manufacturers’ instructions. FACSCalibur (Becton
ickinson)was used for ﬂowcytometry event collection and events
ere analysed using FlowJo (Tree Star Inc.).
.8. Statistical analysis
For the real-time RT-PCR data the mean Ct value of duplicate
apillaries was converted to copy number using external stan-
ard curves generated from puriﬁed and quantiﬁed PCR product.
GF-1 and FoxP3 expression were normalised by dividing copy
umber of gene by copy number of HPRT. Normalised mRNA and
erum protein values within a vaccine group were compared using
he non-parametric Wilcoxon Signed Rank test in SPSS. Corre-
ations between TGF-1 protein, IFN- ELISPOT responses and
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Table 1
Following vaccination an area under the curve analysis (AUC) was carried out between 0 and 12 weeks to measure changes in FoxP3 or TGF-1 mRNA expression
Vaccine group n Median AUC (25th, 75th percentiles)
FoxP3-unstimulated expression FoxP3 85A-stimulated expression TGF-unstimulated expression TGF 85A-stimulated expression
BCG 5 1.34 (1.26–1.63) 1.60 (1.38–1.68) 36.81 (33.53–37.61) 35.62 (34.28–38.30)
BCG–MVA 7 1.43 (0.98–2.12) 1.18 (1.02–1.84) 27.24 (21.15–36.36) 26.65 (17.73–34.39)
MVA 8 1.21 (1.07–1.42) 1.43 (1.19–1.59) 37.84 (31.06–43.30) 37.54 (31.29–44.62)
p-Valuea 0.60 0.43 0.06 0.03
The Kruskall–Wallis test (a global test for the comparison of medians) was performed to identify signiﬁcant changes in gene expression. Data are summarized using median
and interquartile range. Two subjects without data at 12 weeks had to be excluded from the analysis
a Kruskall–Wallis test.
Table 2
The expression of TGF-1 mRNA is signiﬁcantly reduced following vaccination with BCG–MVA85A when compared to BCG alone or MVA85A alone
TGF-unstimulated expression TGF 85A-stimulated expression
Diff in medians (95% CIa) p-Valueb Diff in medians (95% CIa) p-Valueb
BCG–MVA vs. BCG −8.81 (−16.07–2.58) 0.09 −10.32 (−25.53–0.79) 0.06
BCG–MVA vs. MVA −9.63 (−18.74–−0.34) 0.03 −12.47 (−25.67–−2.54) 0.02
BCG vs. MVA −1.83 (−9.86–5.92) 0.66 −2.04 (−9.93–5.73) 0.59
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tide (latency associated propeptide). TGF-1 is also produced by
many cell types, not just PBMC, which may account for the lack
of direct correlation between TGF-1 protein and mRNA in our
study.
Fig. 1. Serum levels of TGF-1 protein are decreased in BCG primed subjects follow-
ingboostingwithMVA85Abutnot in subjects vaccinatedwithBCGaloneorMVA85Ahe Mann–Whitney test was used to determine signiﬁcant differences in gene expr
a Estimated using the Binomial method.
b Mann–Whitney test.
D4+CD25hiFoxP3+ cells were performed using the Spearman’s
ank test in SPSS. Area under the curve analysis was carried out
nd the three groups were compared using the Kruskall–Wallis
est. Where signiﬁcant differences were found between the three
roups, the Mann–Whitney test was used to make all pair-wise
omparisons. These analyses were carried out using STATA.
. Results
.1. TGF-ˇ1 but not FoxP3 mRNA expression is reduced following
accination with MVA85A in BCG primed subjects
The kinetics of FoxP3 mRNA and TGF-1 mRNA expression
ere investigated in BCG naïve or BCG primed subjects following
accination with MVA85A. mRNA was measured on the day of vac-
ination and 1, 4 and 12weeks following vaccination. An area under
he curve analysis (AUC) was carried out between 0 and 12 weeks
o determine differences in expression between the vaccine groups.
signiﬁcant difference in TGF-1 mRNA expression between the
accine groups was seen in PBMC stimulated with 85A peptides
p=0.03) and a weak difference was seen in unstimulated PBMC
p=0.06) (Table 1). There was no signiﬁcant difference in FoxP3
RNA expression between the vaccine groups. A pair-wise test of
GF-1 mRNA expression using Mann–Whitney showed a signiﬁ-
ant decrease in both stimulated and unstimulated TGF-1 mRNA
xpression in BCG primed versus BCG naïve subjects vaccinated
ith MVA85A (p=0.02, 0.03) (Table 2).
.2. TGF-ˇ1 protein is reduced in serum following vaccination
ith MVA85A in BCG primed subjects
TGF-1 mRNA was signiﬁcantly reduced in both peptide-
timulated and -unstimulated PBMC from BCG primed subjects
accinated with MVA85A. TGF-1 protein is secreted as a latent
roprotein which can be activated by acidiﬁcation in vitro. Acid
ctivated serum TGF-1 protein levels were measured pre- and
ost-vaccination to determine if the reduction in TGF-1 mRNA
eﬂected a systemic reduction in TGF-1 protein. There was a
igniﬁcant decrease in serum TGF-1 from day of vaccination
median 4.3ng/ml) toweek 1 (median 3.7ng/ml), atweek 4 TGF-1
a
1
M
T
f
B.
ncreased but remained signiﬁcantly below the day of vaccination
median 4.2ng/ml) and by week 12 TGF-1 levels had decreased
gain (median 3.9ng/ml) (Fig. 1). Following vaccinationwith either
CG alone or MVA85A alone there was no signiﬁcant change in
erum TGF-1 protein (Fig. 1). Although both TGF-1 mRNA and
roteinwere reduced following vaccination of BCGprimed subjects
ithMVA85A therewas no direct correlation of acid activated TGF-
1 protein and mRNA expression (p=0.294). Others have reported
lack of direct correlation between TGF-1 mRNA and protein
[38], #130). This is most likely due to the secretion of TGF-1 as
latent proprotein requiring proteolytic cleavage of the LAP pep-lone. Serum TGF-1 protein levels were measured on the day of vaccination and
, 4 and 12 weeks post-vaccination for subjects vaccinated with BCG alone (n=6),
VA85A alone (n=8) and in BCG primed subjects vaccinated with MVA85A (n=11).
here was a signiﬁcant decrease in serum TGF-1 protein in BCG primed subjects
ollowing boosting with MVA85A, *p=0.0005, **p=0.021, ***p=0.021 (Wilcoxon).
ox and whisker plots showing median, 25th and 75th percentiles.
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Table 3
Higher serum TGF-1 protein on the day of vaccination results in lower IFN- ELISPOT responses to Ag85A peptides 4 months following vaccination with MVA85A alone
Week 1 Week 4 Week 8 Week 12 Week 16 Week 24 Week 52
BCG
Correlation coefﬁcient −0.06 0.23 −0.49 0.05 ND −0.03 ND
p-Value (1− tailed) 0.457 0.329 0.160 0.467 0.478
n 6 6 6 5 6
MVA85A
Correlation coefﬁcient −0.44 −0.77 −0.85 −0.71 −0.81 0.02 ND
p-Value (1− tailed) 0.136 0.020 0.004 0.024 0.007 0.484
n 8 7 8 8 8 7
BCG–MVA85A
Correlation coefﬁcient −0.07 −0.10 ND −0.16 ND −0.53 −0.57
p-Value (1− tailed) 0.416 0.385 0.315 0.059 0.090
11 10 7
T s serum TGF-1 was correlated (Spearman’s correlation) with IFN- ELISPOT responses
f CG primed subjects.
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with TGF-ˇ1 serum protein and SK/SD IFN- ELISPOT responses
TGF-1 can either directly regulate effector T cells or indi-
rectly regulate effector T cells through the activity of regulatoryn 11 11
o determine if TGF-1 protein at week 0 could effect long-term memory response
ollowing vaccination with BCG alone, MVA85A alone and MVA85A vaccination of B
.3. Higher serum TGF-ˇ1 protein on the day of vaccination
esults in lower IFN- ELISPOT responses to Ag85A peptide up to 4
onths following vaccination with MVA85A alone
To determine if TGF-1 protein atweek 0 could effect long-term
emory responses serum TGF-1 was correlated (Spearman’s cor-
elation) with IFN- ELISPOT responses following vaccination with
CG alone, MVA85A alone and BCG primed subjects vaccinated
ith MVA85A. There was no relationship between serum TGF-1
nd peptide responses to BCG at any time point. TGF-1 protein
t week 0 inversely correlated with IFN- ELISPOT responses at
eeks 4, 8, 12 and 16 following vaccinationwithMVA85A. The rela-
ionship was lost at weeks 24 following vaccination with MVA85A,
owever, the peptide IFN- ELISPOT response was undetectable (0
pots) in many volunteers at this time point which may account for
he lack of correlation with TGF-1. In contrast, when MVA85A is
dministered to BCG primed subjects there is little correlationwith
GF-1 protein and IFN- ELISPOT responses at the earlier time
oints. Presumably because TGF-1 is reduced in BCG primed sub-
ects vaccinated with MVA85A. However, there is a trend towards
igniﬁcance at the later time points (weeks 24 and 52) (Table 3).
.4. Immune responses to the recall antigen SK/SD are increased
n BCG primed subjects following vaccination with MVA85A
To determine if the reduction in TGF-1 serum protein could
ead to a non-speciﬁc enhancement of effector T cell responses
n vaccinated subjects IFN- ELISPOT responses to the recall anti-
en SK/SD were determined at weeks 0, 1, 4 and 12. SK/SD
esponses were signiﬁcantly enhanced in BCG primed subjects at
eek 1 (median=292SFC/million) returned to baseline at week 4
median=107SFC/million) and were enhanced again at week 12
ost-vaccination with MVA85A (median=307SFC/million) (Fig. 2).
his bi-modal increase in the SK/SD ELISPOT response seems to be
he inverse of that seen with TGF-1 protein in the serum. SK/SD
esponses were unchanged following vaccination with either BCG
lone or MVA85A alone (data not shown).
.5. SK/SD recall responses in BCG primed subjects are inversely
roportional to TGF-ˇ1 serum protein levels
Spearman’s correlation was performed to determine if the
ncrease in immune response to recall antigen could be related to
he decrease in TGF-1 mRNA or serum protein. The SK/SD IFN-
LISPOT responses atweek1were signiﬁcantly inversely correlated
o TGF-1 serum protein but not TGF-1 mRNA in BCG primed
ubjects (p=0.008) (Fig. 3).
F
o
oig. 2. Immune responses to the recall antigen SK/SD are increased at both weeks
and 12 in BCG primed subjects vaccinated with MVA85A (n=9) (Wilcoxon). Box
nd whisker plots showing median, 25th and 75th percentiles.
.6. Inverse correlation of CD4+FoxP3+ CD25high lymphocytesig. 3. The immune response to the recall antigen SK/SD (fold change of week 1
ver week 0) is inversely proportional to TGF-1 serum protein levels (fold change
f week 1 over week 0). n=9, R=−0.769, p=0.008 (Spearman’s correlation).
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tional level as we see a reduction in TGF-1 mRNA in the PBMC of
vaccinated subjects. TGF-1 is a key regulator of the signaling path-
ways that initiate and maintain FoxP3 expression and is essential
for the generation and suppressive function of peripheral regula-ig. 4. The percentage of CD4+CD25hiFoxP3+ T cells 1 week post-vaccination of BCG
he percentage of total CD4+CD25 high FoxP3 expressing cells in the lymphocyte gat
ere selected from within the CD4+CD25high gate. Representative plots from 1 of 6
cells with fold change in TGF-1 protein expression and SK/SD ELISPOT response.
cells. CD4+CD25hi cells express high levels of FoxP3 and are a
ighly efﬁcient regulatory subset of the CD25+ population [20].
he percentage of CD4+CD25hiFoxP3+ cells, 1 week following vac-
ination with MVA85A, in the PBMC of six BCG primed subjects
accinated with MVA85A were determined using ﬂow cytome-
ry. To determine where the CD25hi population lay, a dot plot
howing the distribution of CD25 versus CD4 was used (Fig. 4A).
oxP3+ lymphocytes were selected within the CD4+CD25hi gate
Fig. 4B). The percentage of CD4+CD25hiFoxP3+ cells in PBMC
nversely correlated with SK/SD IFN- ELISPOT responses in BCG
rimed subjects vaccinated with MVA85A (p=0.018, Fig. 4C). The
ercentage of CD4+CD25hiFoxP3+ cells 1 week post-vaccination
ositively correlated with TGF-1 protein in the serum of BCG
rimed subjects (p=0.008, Fig. 4C). There was no correlation
etween CD4+CD25hiFoxP3+ cells with IFN- ELISPOT responses
o 85A peptides or PPD (data not shown).
.7. Treatment of PBMC with anti-IFN- antibodies increases the
xpression of TGF-ˇ1 mRNA
A possible mechanism for the reduction in TGF-1 mRNA in
he BCG primed group is that the higher level of antigen-speciﬁc
FN- in the BCG prime–MVA85A boost group favors the down-
egulation of TGF-1 signaling and mRNA production. Cells from
ve BCG primed subjects vaccinated with MVA85A were cultured
ith 85A peptides and IFN- blocking antibodies. Blocking IFN-
amma signiﬁcantly increased TGF-1 mRNA expression in these
ubjects (p=0.016) (Fig. 5).. Discussion
The vaccination of BCG primed subjects with MVA85A induces
evels of IFN- secreting effector T cells approximately 10 times
F
T
I
sd subjects with MVA85A are inversely proportional to the SK/SD ELISPOT response.
determined by (A) gating on CD4 positive CD25high cells. (B) FoxP3 expressing cells
cts are shown. (C) Spearman’s correlation of the percentage of CD4+CD25hiFoxP3+
reater than those reported for any other recombinant MVA
3,4,6–8,21–23]. BCG vaccination induces Ag85A-speciﬁc mem-
ry T cells and Ag85A is also present in many environmental
ycobacteria. MVA85A therefore has a potentially large pool of
g85A-speciﬁc memory T cells that could be expanded into IFN-
secreting effector T cells. In this current study we have also found
hat vaccination with MVA85A in BCG primed but not BCG naïve
ubjects leads to a reduction in serumTGF-1 protein. Althoughwe
ee no direct correlation between protein and mRNA, the reduction
n TGF-1 serum protein is likely to be controlled at the transcrip-ig. 5. Treatment of PBMC with anti-IFN- antibodies increases the expression of
GF-1 mRNA. IFN- can lead to a down-regulation in TGF-1 signaling. Blocking
FN- leads to a signiﬁcant increase in TGF-1 mRNA expression in BCG primed
ubjects 4 weeks post-vaccination with MVA85A, *p=0.016 (Wilcoxon).
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ory T cells [13,17,18]. However, we saw a transient increase rather
han a decrease in the expression of FoxP3 mRNA. It is known that
oxP3 mRNA is transiently expressed by T cells upon activation and
hat this does not commit cells to a regulatory phenotype [24].
he changes in FoxP3 mRNA expression we observe in response
o MVA85A vaccination are likely to be a result of T cell activation
ather than T cell regulation.
Previously we have found that TGF-1 is associated with the
eneration of regulatory T cells and higher rates of parasitic growth
n subjects infected with P. falciparum [19]. In murine studies, we
nd others recently found that depletion of regulatory T cells using
monoclonal antibody to CD25 enhances the immunogenicity of
variety of vaccine types including BCG and MVA85A [25,26]. In
ur current study the decrease in TGF-1 serum protein inversely
orrelated with an increase in IFN- ELISPOT response to the recall
ntigen SK/SD. The effect appears to be bi-modal with both TGF-1
nd SK/SD responses returning close to baseline at week 4 before
ecoming reduced/increased again at week 12. We found that both
GF-1 serum protein and SK/SD IFN- ELISPOT responses cor-
elated with the percentage of CD4+CD25hiFoxP3+ T cells in BCG
rimed subjects. The increase in ELISPOT response to recall antigen
ay therefore be a result of systemic reduction in TGF-1 protein
nd subsequent reduction in the number of peripheral regulatory
D4+CD25hiFoxP3+ T cells. Alternatively, T cells can bedirectly reg-
lated through binding of active TGF-1 with the TGF-1RI and
GF-1RII cell surface receptors. It has recently been found that
erum TGF-1 is the most prominent factor actively keeping CD4+
cells in a resting state [27]. Classens et al. found that the removal
f even low physiological concentrations of TGF-1 had a func-
ional effect on CD4+ T cells, leading to enhanced proliferation in
esponse to low level TCRsignaling. Interestingly, despite thecapac-
ty of viral vectors to boost a CD8 response, the antigen-speciﬁc
esponse following vaccination with MVA85A has been exclusively
CD4+ response (when measured by IFN- ELISPOT) [11,12]. This
ay be due to enhanced activation and proliferation of CD4+ T
ells in response to lowered TGF-1 serum concentrations. High
GF-1 serum protein appears to correlate with reduced effector T
ell responses to MVA85A in BCG naïve subjects. However, in BCG
rimed subjects effector T cell responses are higher and there is
o association with TGF-1. Down-regulation of TGF-1 is likely,
t least in part, to account for the sustained high levels of antigen-
peciﬁc effector T cells seen after vaccination with MVA85A in BCG
rimed subjects, perhaps through a reduction in the number of
irculating regulatory T cells.
Plasma TGF-1 levels are predominantly under genetic con-
rol [28]. However, IFN- can directly regulate TGF-1 through the
TAT and SMAD pathways [29]. One possible mechanism for the
eduction in TGF-1 is that the high level of antigen-speciﬁc IFN-
eleased following vaccination with MVA85A leads to a down-
egulation of TGF-1 mRNA via expression of SMAD 7 [29]. Indeed,
e have found that blocking IFN- leads to an increase in antigen-
peciﬁc TGF-1 mRNA expression. There is strong evidence for
GF-1-dependent immune regulation in tuberculosis infection.
hen compared tohealthy controls, TBpatients havebeen found to
ave reduced IFN- production and increased TGF-1 in response
o stimulation with mycobacterial antigens [30–33]. Neutralising
GF- leads toenhanced immune responses andclearanceof tuber-
ulosis infection [30,32,34]. There is also evidence for theexpansion
f FoxP3 expressing regulatory T cells during tuberculosis infection
35–37].Although the number of subjects in our study is small, we have
een that vaccination of BCG primed subjects with MVA85A results
n reduced TGF-1 mRNA in PBMC and reduced TGF-1 protein in
he serum of vaccinated subjects. This appears to limit the number
f circulating CD4+CD25hiFoxP3 positive T cells and enhance IFN-
[6 (2008) 5269–5275
responses to the recall antigen SK/SD. Therefore, in BCG primed
ndividuals theremaybeaperiodof timeshortly followingMVA85A
accinationwhere greater effector T cell responses could be elicited
rom a less immunogenic vaccine. This raises the possibility of
esigning vaccine schedules for TB, HIV and malaria whereby the
accine for TB aids in the generation of protective immunity against
IV and malaria.
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